Seroneutralization of Omicron BA.1 and BA.2 in patients receiving anti-SARS-CoV-2 monoclonal antibodies.

Timothee Bruel; Jerome Hadjadj; Piet Maes; Delphine Planas; Aymeric Seve; Isabelle Staropoli; Florence Guivel-Benhassine; Francoise Porrot; William-Henri Bolland; Yann Nguyen; Marion Casadevall; Caroline Charre; Helene Pere; David Veyer; Matthieu Prot; Artem Baidaliuk; Lize Cuypers; Cyril Planchais; Hugo Mouquet; Guy Baele; Luc Mouthon; Laurent Hocqueloux; Etienne Simon-Loriere; Emmanuel Andre; Benjamin Terrier; Thierry Prazuck; Olivier Schwartz.
Preprint en Inglés | PREPRINT-MEDRXIV | ID: ppmedrxiv-22272066

Documentos relacionados

  1. Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies.
  2. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization.
  3. Clinical and Virological Outcome of Monoclonal Antibody Therapies Across SARS-CoV-2 Variants in 245 Immunocompromised Patients: A Multicenter Prospective Cohort Study.
  4. Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies.
  5. Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies.
  6. Serum neutralization of SARS-CoV-2 Omicron BA.2, BA.2.75, BA.2.76, BA.5, BF.7, BQ.1.1 and XBB.1.5 in individuals receiving Evusheld.
  7. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants.
  8. Susceptibility of SARS-CoV-2 Omicron Variants to Therapeutic Monoclonal Antibodies: Systematic Review and Meta-analysis.
  9. A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern.
  10. Targeted SARS-CoV-2 treatment is associated with decreased mortality in immunocompromised patients with COVID-19.